UNASSIGNED: BACKGROUND The purpose of this study was to evaluate the effect of @entity737 ( @entity737 ) in @entity712 ( @entity712 ) @entity1 compared to pharmacologic/conventional management. MATERIAL AND METHODS We searched PubMed, Embase, and Springer Link Library databases up to February 10th, 2014. Pooled risk ratio (RR) and 95% confidence interval (CI) for the mortality of the @entity1 with @entity712 were collected and calculated in a fixed-effects model or a random-effects model, as appropriate. Summary effect estimates were also stratified by sex and follow-up time. Egger's regression asymmetry tests were utilized for publication bias detection. RESULTS A total of 7 separate studies including 15 520 @entity1 (10 801 @entity737 cases and 4719 controls) with @entity712 were considered in the meta-analysis. The overall estimates showed that @entity737 could statistically significantly reduce the mortality of male (RR=0.73, 95% CI: 0.66-0.80) and female (RR=0.75, 95% CI: 0.63-0.90) @entity1 . In addition, the further stratification subgroup analysis indicated that @entity737 presented a significant reduction (male: RR=0.72, 95% CI: 0.64-0.81; female: RR=0.69, 95% CI: 0.56-0.85) of mortality after 2-3 years of @entity737 therapy. The RR (95% CI) effects of mortality after 4-5 years of @entity737 therapy for males and females were 0.76 (0.51-1.14) and 0.96 (0.68-1.37), respectively. CONCLUSIONS This meta-analysis suggests that @entity737 could reduce @entity712 @entity1 mortality despite the sex difference.

Use of Implantable Cardioverter Defibrillators in @entity712 XXXX and Risk of Mortality: A Meta-Analysis.

@entity737 :: ('MESH:D057873', 'Disease') :: ['ICD', 'implantable cardioverter defibrillators'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity712 :: ('MESH:D006333', 'Disease') :: ['HF', 'heart failure']
@entity1 :: (9606,Species) :: ['Patients']
